Statin therapy for ASCVD prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 14: Line 14:
*CK
*CK
*Consider evaluation for other secondary causes
*Consider evaluation for other secondary causes
*
 
{| class="wikitable"
{| class="wikitable"
!Secondary Cause
!Secondary Cause
Line 26: Line 26:


Anorexia nervosa
Anorexia nervosa
|Weight gain,
|Weight gain  
Very-low-fat diets
Very-low-fat diets


Line 47: Line 47:
Bile acid sequestrants
Bile acid sequestrants


Protease inhibitors, Retinoic acid,
Protease inhibitors
 
Retinoic acid
 
Anabolic steroids


Anabolic steroids, sirolimus,
Sirolimus


Raloxifene,
Raloxifene  


Tamoxifen
Tamoxifen

Revision as of 21:40, 27 October 2016

Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Major Recommendations for Statin Therapy for ASCVD Prevention

The following is a treatment algorithm proposed by the AHA/ACC guidelines committee:[1]

Initial evaluation prior to statin initiation

Initial evaluation prior to statin initiation include:

  • Fasting lipid panel
    • Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level !220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are !500 mg/dL, a fasting lipid panel is required.
  • ALT
  • CK
  • Consider evaluation for other secondary causes
Secondary Cause Elevated LDL-C Elevated Triglycerides
Diet Saturated or trans fats

Weight gain

Anorexia nervosa

Weight gain

Very-low-fat diets

High intake of refined carbohydrates

Excessive alcohol intake

Drugs Diuretics

Cyclosporine

Glucocorticoids

Amiodarone

Oral estrogens

Glucocorticoids

Bile acid sequestrants

Protease inhibitors

Retinoic acid

Anabolic steroids

Sirolimus

Raloxifene

Tamoxifen

Beta blockers

Diseases Biliary obstruction

Nephrotic syndrome

Nephrotic syndrome

Chronic renal failure

Lipodystrophies

Disorders and altered states of metabolism Hypothyroidism

Obesity

Pregnancy

Diabetes (poorly controlled)

Hypothyroidism

Obesity

Pregnancy

  1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH; et al. (2014). "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S1–S45. doi:10.1161/01.cir.0000437738.63853.7a. PMID 24222016.


Template:WikiDoc Sources CME Category::Cardiology